ArticleAmerican journal of translational research2025
Dapagliflozin combined with sacubitril/valsartan promotes cardiac function recovery in elderly patients with acute myocardial infarction.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the clinical efficacy of dapagliflozin combined with sacubitril/valsartan for heart failure (HF) in elderly patients with Acute Myocardial Failure (AMI) post emergency Percutaneous Coronary Intervention (PCI) and their effects on patients' cardiac function recovery, inflammatory status, and prognosis.
methodsThis retrospective study included 94 elderly AMI patients who developed HF after emergency PCI at Tangshan Gongren Hospital between May 2022 and March 2024. Based on their treatment regimen, the enrolled patients receiving sacubitril/valsartan only were categorized as the control group (n=43), and those who underwent sacubitril/valsartan plus dapagliflozin as the study group (n=51). Patients in both groups were all treated for 12 weeks. Their cardiac function indicators, such as left ventricular ejection fraction (LVEF), HF biomarkers, including B-type natriuretic peptide (BNP), inflammatory factors, such as interleukin-6 (IL-6), tumor necrosis factor-alpha and high-sensitivity C-reactive protein, ventricular remodeling measures, 6-minute walk test (6MWT), quality of life [measured by the scores of Minnesota Living with Heart Failure Questionnaire (MLHFQ)], major adverse cardiac events (MACEs), and adverse drug reactions were compared before and after treatment.
resultsAfter 12-week treatment, the study group showed a marked increase in LVEF (60.3±6.2 vs 54.1±5.7, P < 0.001), a significant reduction in BNP level (23.20±5.12 vs 27.64±4.66 pmol/L, P < 0.001) and in levels of inflammatory factors including (IL-6: 113.25±40.55 vs 142.72±31.20 pg/L, P < 0.001), better performance in 6MWT (447.11±34.08 vs 406.24±31.77 m, P < 0.001), as well as a significant decrease in MLHFQ scores (38.04±4.30 vs 45.51±5.12, P < 0.001) in comparison to the control group. Additionally, patients in the study group demonstrated lower rate of MACE occurrence compared to the control group (9.80% vs 25.58%, P=0.043). However, no significant differences were observed in adverse drug reactions between the two groups (9.80% vs 6.98%, P=0.906).
conclusionDapagliflozin combined with sacubitril/valsartan can significantly facilitate cardiac function recovery, reduce inflammatory response, enhance exercise tolerance and quality of life, and lower the risk of MACE in elderly AMI patients who developed HF following emergency PCI. The regimen had a favorable safety profile, suggesting good clinical implications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.